Effect of Evolocumab on Non‐High‐Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies

BACKGROUND: Dyslipidemia guidelines recommend non‐high‐density lipoprotein cholesterol (non‐HDL‐C) and apolipoprotein B (ApoB) as additional targets of therapy and consider lipoprotein(a) a significant cardiovascular risk marker. The current analysis evaluates the effects of evolocumab on these para...

Descripción completa

Detalles Bibliográficos
Autores principales: Toth, Peter P., Jones, Steven R., Monsalvo, Maria Laura, Elliott‐Davey, Mary, López, J. Antonio G., Banach, Maciej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7335559/
https://www.ncbi.nlm.nih.gov/pubmed/32114889
http://dx.doi.org/10.1161/JAHA.119.014129

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7335559/
https://www.ncbi.nlm.nih.gov/pubmed/32114889
http://dx.doi.org/10.1161/JAHA.119.014129

Ejemplares similares